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Hypoglycaemia Unawareness
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Abstract
Hypoglycaemia is the most frequent and serious complication of insulin therapy and is three times
more common in those who are intensively treated. Impaired awareness of hypoglycaemia is a major
limitation to achieving tight diabetes. Asymptomatic biochemical hypoglycaemia occurs more frequently
during routine blood glucose monitoring and this should alert the clinician that the individual is developing
hypoglycaemic unawareness. Though the etiology of hypoglycaemic unawareness is multifactorial, possible
mechanisms include chronic exposure to low blood glucose, antecedent hypoglycaemia, recurrent
severe hypoglycaemia and the failure of counter-regulatory hormones.
Diabetic patients with history of impaired awareness of hypoglycaemia perform poorly on cognitive
function testing and this may be restored by relaxation of glycaemic control. The question of whether
human insulin produces hypoglycaemia awareness has been hotly debated but this does not appear to
be a major problem considering the number of patients on human insulin. The decision to use one or
other of the insulins therefore rests entirely with the physician.
Low blood glucose awareness training programmes can help to identify and prevent hypoglycaemia
unawareness. Impaired awareness of hypoglycaemia can probably be reversed by scrupulous avoidance
of hypoglycaemia. ©
of neural tissue on a continuous supply of glucose,
interruption of which for more than a few minutes leads to
central nervous system dysfunction, impaired cognition and
eventually coma.
Epidemiology
As the evidence emerged that tight metabolic control
reduced the risk of microvascular complications, early
attempts to maintain near normal glucose levels led to frequent
and severe hypoglycemic episodes. The risk is three times
greater in the group undertaking intensive therapy, in which
the glucose targets were close to normal.1 It is apparent that
impaired awareness of hypoglycaemia is a major risk factor
for severe hypoglycaemia. In the DCCT, 36% of all episodes
of severe hypoglycaemia occurred with no warning symptoms
in patients who were awake.4 Impaired awareness of
hypoglycaemia is common in people treated with insulin.
While the chronic form of this acquired condition mainly
affects those with type 1 diabetes, the risk also increases in
people with progressive beta cell failure (insulin treated type-
2 diabetes). In the UKPDS, the proportion of major
hypoglycaemic events per year for first 10 years was 0.4% for
chlorpropamide, 0.6% for glibenclamide and 2.3% for insulin.2
The rates of hypoglycaemia rose as the duration and number
of people treated with insulin therapy increased, with almost
50% of patients experiencing hypoglycaemia without warning
symptoms after 25 years or more of treatment.5
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INTRODUCTION
Hypoglycemia is the most common and most seriouscomplication of insulin therapy. It is the major obstacle
to improved glycaemic control through intensified insulin
therapy. It should be remembered that for many patients (and
their families), it is the most terrifying and disabling aspect of
the diabetic control. The Diabetes Control and  Complications
Trial (DCCT),1 the United Kingdom Prospective Diabetes
Study (UKPDS)2 and the other studies of intensive therapy,3
showed that the frequency of hypoglycemia was higher in
those who achieved tight diabetes control. Development of
symptoms in response to a low blood glucose level provides
a fundamental defence for the brain, by alerting the affected
individual to the imminent development of neuroglycopenia,
which provokes an appropriate response - ingesting some
form of carbohydrate to reverse the decline in blood glucose.
Failure of these warning symptoms to occur or delay in their
occurrence until the blood glucose has fallen to a level which
causes disabling neuroglycopenia, can have serious
consequences. The crucial factor that makes hypoglycemia
so important in the management of diabetes is the dependence
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Definition of hypoglycemic unawareness
No satisfactory definition of hypoglycaemic unawareness
has been suggested to date. A simple definition for
hypoglycaemia unawareness would be reduced ability or
failure to recognise hypoglycemia at the physiological plasma
glucose concentration at which warning symptoms normally
occur. Asymptomatic biochemical hypoglycaemia occurs
more frequently during routine blood glucose monitoring in
diabetic patients who report impaired awareness of
hypoglycemia, and such a record may alert the clinician to
the possibility that an individual is developing this problem.
Patients unaware of hypoglycemia either do not realise that
the plasma glucose is decreasing and causing
neuroglycopenia, or ultimately feel the symptoms, but at much
lower plasma glucose levels (high thresholds). In older text
books, hypoglycemia is usually defined as plasma glucose
concentration below 50 mg/dl (2.7 mmol/l).6,7 However,
normally the release of counter-regulatory hormones in
response to hypoglycemia is already evident for modest
decrements in plasma glucose i.e. at a plasma glucose
concentration of 65 mg/dl (3.5 mmol/l). Thus a modern
physiological definition of hypoglycemia is any decrease in
plasma glucose concentration below 65 mg/dl (3.5 mmol/l).
This concept is important not only in physiology, but also to
define the safe glycaemic targets for intensive therapy of
Type 1 diabetes.8,9
Classification
Hepburn et al,10 subdivided hypoglycemia awareness into
the following categories.
a. Normal awareness: The individual is always aware of
the onset of hypoglycemia.
b. Partial awareness: The symptom profile has changed
with a reduction either in the intensity or in the number
of symptoms and in addition, the individual may be aware
of some episodes of hypoglycemia but not of others.
c. Absent awareness: The individual is no longer aware of
any episode of hypoglycemia.
In assessing the present state of hypoglycaemia
awareness, it is desirable that the patient should have
experienced one or more episode of hypoglycaemia within a
defined time interval. Because hypoglycaemia awareness and
its impairment lie on a continuum ranging from normality to
complete inability to detect the onset of hypoglycaemia, a
comparison can be made with earlier episodes of
hypoglycaemia. Although, the subdivision into partial and
absent awareness is artificial, it reflects the natural history of
this clinical problem with a gradual progression of this
disability, although total absence of clinical manifestation of
hypoglycaemia (particularly the neuroglycopenic features)
is extremely rare.11 The impact of complete hypoglycemia
unawareness on the affected individuals and their families is
often devastating. The chances of suffering a severe attack
increases 6-7 fold in those with unawareness, even during
standard therapy12 and such patients are usually excluded
from attempting intensified insulin therapy .
Pathogenesis of hypoglycemia unawareness
The first response as the blood glucose concentration
falls below normal is the acute release of counter-regulatory
hormones (glucagon and epinephrine) which occurs at a
plasma glucose level of 65-68 mg/dl.13 If the blood glucose
continues to fall, autonomic symptoms begin to appear
around 58 mg/dl.14 Cognitive function as measured by reaction
time and other psychomotor tasks, starts to deteriorate around
54 mg/dl.15 The protective glucagon response to
hypoglycaemia, which is normal at diagnosis, begins to fail
within 1-2 years duration in Type 1 diabetic subjects and
after five years, an impaired or absent response is almost
universal. The cause however remains unclear.16 It appears
unrelated to autonomic neuropathy. The pancreatic alpha
cells fail to recognize hypoglycemia as a stimulus for release
of glucagon but it is secreted normally in response to alanine.
Perhaps, the most convincing hypothesis is the disruption
of paracrine insulin cross task within the islets. A reduced
sympathoadrenal response is also common in established
diabetes, although the degree of impairment is more variable
and it occurs after a longer duration of diabetes.17 Epinephrine
response to other stimuli such as exercise appears to be normal
which is therefore also a selective failure of hypoglycemia
recognition. Paraplegic patients with high cervical transection
of the cord lose epinephrine secretion and the autonomic
response to hypoglycaemia and simply fall into deep sleep.18
Chronic hypoglycaemia in particular, appears to increase
the expression of glucose transporters localized in the
microvessels of the blood brain barrier (GLUT-1) as well as
the neuron-specific glucose transporters (GLUT-3).19 In
diabetic patients with low values of glycosylated
haemoglobin (HbA1c) due to antecedent, frequent
hypoglycemia, brain glucose uptake does not decrease during
hypoglycaemia as it does in uncontrolled diabetic patients
with elevated HbA1c (less frequent hypoglycaemia) and in
non-diabetic subjects.20 Thus during subsequent
hypoglycemia, the brain is less neuroglycopenic than normal
and does not need to generate the counter-regulatory
responses and the autonomic symptoms to defend and alert
the subject about hypoglycaemia.This is the mechanism of
cerebral adaptation causing impaired awareness of
hypoglycaemia in chronic and antecedent (episodic)
hypoglycaemia (Fig. 1). An additional mechanism of
hypoglycaemia unawareness has been provided by Davis et
al21 who proposed that the responses of cortisol to antecedent
hypoglycemia blunt the autonomic hormone response to
subsequent hypoglycaemia and vice versa. Recently,
McGregor et al22 found reduced autonomic responses to
hypoglycaemia after antecedent increase of cortisol levels
by infusion of adrenocorticotropic (ACTH) hormone in
healthy subjects. Interestingly, over the last decade, several
studies have shown that alpha-adrenergic sensitivity is
reduced in Type 1 diabetic patients and that antecedent
hypoglycemia itself reduces alpha adrenergic sensitivity of
subsequent hypoglycaemia, thus favouring the generation
of hypoglycaemia unawareness.23
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Moreover, there is some evidence that patients with
established autonomic neuropathy may have an additional
defect in epinephrine release during hypoglycaemia.24 The
term hypoglycaemia associated autonomic failure (HAAF)
has been used to describe the specific defect of autonomic
responses during hypoglycaemia and this term was
introduced to distinguish this condition from classical
autonomic neuropathy.25 The possible mechanisms of
impaired awareness of hypoglycaemia in certain clinical
situations are discussed in Table 1.
Does human insulin increase risk of hypoglycemic
unawareness?
More recently, the most contentious issue is whether the
species of insulin affects awareness of hypoglycaemia,
specifically, whether human insulin affects the epinephrine
response. Despite extensive research efforts, the question of
whether human insulin affects the awareness of
hypoglycaemia remains unproven. Berger et al26 in a double
blind, randomized cross-over trial of human and porcine
insulins reported that the initial symptoms seemed more often
to be ‘adrenergic’ with porcine and ‘neuroglycopenic’ with
human insulin. However most of the studies which were
performed in patients who specifically claimed to have
developed impaired awareness of hypoglycaemia after being
changed to human insulin showed no differences in the
hormonal or symptomatic responses to hypoglycaemia.27 The
only exception is the study by Teuscher et al, 28 where they
claim that patients experienced more frequent hypoglycaemia,
altered warning symptoms and impaired awareness of
hypoglycaemia with the use of human insulin. A number of
attempts world over have been made to answer this question,
including a recent Cochrane review which compared the
effects of human insulin and animal insulins in diabetic
patients from 1996 to May 2002.29 It was concluded that both
human and animal insulins are equally good and the decision
to use one or other of the insulin rests entirely with the
physician. In the authors’ view also there does not appear to
be any hypoglycaemia unawareness issue with human insulin
given the fact that thousands of patients have been treated
with human insulin. Therefore the decision of choosing a
particular insulin ultimately falls upon the physician who
should make the right choice depending on the diagnosis,
expected clinical outcome and the affordability of the patient.
While changing over from animal to human insulins, however
it is prudent to start with a slightly lower insulin dose.
Complications of hypoglycaemic unawareness
Hypoglycaemia unawareness can cause a wide range of
neurological symptoms and clinical signs which can be subtle
or severe, reversible or permanent. Impaired awareness of
hypoglycaemia is a major risk factor for severe
hypoglycaemia.4 Long term neurological manifestations of
severe insulin induced hypoglycaemic unawareness are
motor/sensory hemiparesis, choreo-athetosis, epilepsy, brain
stem syndrome and psychological manifestations including
cognitive impairment with behavioral abnormalities and
automatism. Children with Type 1 diabetes who suffer repeated
and severe hypoglycaemia when below five years of age have
lower mental abilities later on in life and may have behaviour
problems.30 Severe hypoglycaemia has a detrimental effect
on cognitive functions as well.31,32 Limited evidence from
prospective studies, namely the Diabetes Control and
Complications Trial (DCCT) and the Stockholm Diabetes
Intervention Study33 indicate that cognitive function does
not deteriorate in patients who suffer recurrent
hypoglycaemia, at least in the time scale (less than 10 years)
of these studies.  However, it must be borne in the mind that
participants in these studies were young, highly motivated,
above average in intelligence, free of advanced complications,
with no history of severe hypoglycaemia before entering the
study and they also received a very high level of support
from health professionals. The formal measurement of
cognitive function during controlled hypoglycaemia (blood
glucose around 45mg/dl) showed that patients with Type 1
Fig. 1 : Schematic diagram on the development of hypoglycaemia
unawareness
Table 1 : Possible mechanism of hypoglycaemic
unawareness in certain clinical situations.
Clinical situation Possible mechanism
1. Increasing duration * Possibly repeated hypoglycemic
of  diabetes damage to glucosensitive neurons.
2. Tight metabolic Antecedent hypoglycemia leading to:
control * up-regulation of neuronal glucose
transport
* Altered catecholamine sensitivity
3. Alcohol * Suppression of autonomic peripheral
responses (tremor)
* Impaired cognition
4. Nocturnal * Sleep and supine position preventing
recognition of early symptoms
(reducing sympatho-adrenal response).
5. Children * Lack of abstract thought
* Prominence of behavioural change
6. Elderly * Prominence of impaired cognition
* Possible reduced autonomic response
* Reduced adrenergic sensitivity
7. Pregnancy * Improved glycaemic control
* Acquired defects in the physiological
response to hypoglycaemia.
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diabetes who had impaired hypoglycaemia awareness
exhibited more profound cognitive dysfunction during acute
hypoglycaemic episodes than those with normal awareness
and that this persisted for longer periods following recovery
of blood glucose.34 Intellectual activity is likely to be affected
and cause sub-optimal performance during this recovery
period. This has implications for skilled tasks such as driving
or operating machinery and equipment. Symptomatic and
neuroendocrine responses to hypoglycaemia in insulin treated
diabetes are diminished in hypoglycaemia unawareness in
association with strict glycaemic control (HbA1c in non-
diabetic range), antecedent (episodic) hypoglycaemia and
chronic (protracted) hypoglycaemia and this may be restored
by relaxation of glycaemic control or scrupulous avoidance
of hypoglycaemia. The changes in the EEG are not specific
for hypoglycaemia, but resemble those seen in hypoxia and
other metabolic encephalopathies.35 Cerebral edema is a
dreaded albeit rare complication of severe insulin induced
impaired awareness hypoglycaemia and should be suspected
if further deterioration or false localising signs ensue. This is
often very resistant to treatment and is usually fatal. Urgent
imaging of the brain is imperative to exclude other potentially
remediable causes of neurological abnormalities or coma.
Prevention and management
Prevention of hypoglycaemia unawareness is an important
part of modern day intensive diabetes therapy. Subcutaneous
insulin replacement is so imperfect that mild hypoglycemia in
inevitably induced from time to time, which in turn induces
unawareness of hypoglycaemia. In theory, if one were able to
prevent hypoglycaemia from the clinical onset of diabetes,
hypoglycaemia unawareness should never occur. In fact,
meticulous prevention of hypoglycaemia in diabetic patients
previously suffering from recurrent hypoglycemia, fully
reverses the syndrome of hypoglycaemia unawareness and
impaired release of adrenaline in short term diabetes.36
 Altered physiological responses to hypoglycaemia suggests
that these defects are functional rather than structural, that
they might be reversible, at least in part, by strict avoidance
of hypoglycemia. The central aim of a hypoglycemia - reversal
programme is to prevent any period of hypoglycemia for
atleast four weeks. A patient who lives in fear of hypoglycemia
will never achieve adequate glycemic control. Appropriate
education includes an emphasis on regular snacks at right
times, warnings to take special care at periods of greater risk
(before lunch and around tea), moderation in alcohol intake,
driving and advise on the amount of carbohydrate needed to
control symptoms. Patients should also be educated about
the danger of delayed hypoglycemia after heavy alcohol
intake or prolonged exercise. Education, reassurance and a
determined attempt should be made to eradicate the problem.
Blood glucose targets should be relaxed but not abandoned.
These are the essential components of a hypoglycaemia
reversal programme. Is there a safe range of HbA1c? Pampanelli
et al 8 studied physiological responses in patients with Type
1 diabetes undertaking intensive insulin therapy. The rates
of severe hypoglycaemia were increased among those with
HbA1c<6% and therefore it was suggested that using current
therapy, an HbA1c of between 6-7% represents the best
compromise between the risk of severe hypoglycemia and
that of developing microvascular complications. The place
of rapid acting insulin analogues in preventing or reversing
hypoglycaemia unawareness is yet to be determined. An
alternative approach is to use continuous subcutaneous
insulin infusion (CSII), especially at night, as this leads to
reduced hypoglycemic episodes and improved counter-
regulatory and symptomatic responses to hypoglycemia in
patients with Type 1 diabetes.37 Table 2 summarizes the
treatment strategies for patients with impaired hypoglycemic
awareness.
Table 2 : Treatment strategies for patients with
impaired awareness of hypoglycemia
* Frequent blood glucose monitoring (including nocturnal
measurements).
* Avoid blood glucose values <65mg/dl.
* Avoid HbA1c in non-diabetic range (target range is relaxed but
not abandoned).
* Use predominantly, short-acting insulins (e.g. Basal-bolus regimen;
insulin analogues, CSII).
* Appropriate education on regular snacks between meals and at
bed time, containing unrefined carbohydrate, and counseling
regarding alcohol and exercise schedules.
* Continuing repetitive and timely education, reassurance and a
determined approach.
* Patients should be educated about subtle neuroglycopenic
symptoms.(Blood glucose awareness training programmes (BGAT)
may help.
CONCLUSIONS
Taken together, these observations indicate that frequent
hypoglycemia in Type 1 diabetes, caused either by
inappropriate treatment and /or impaired counter-regulation,
rapidly induces loss of symptoms and blunts the release of
counter-regulatory hormones in response to hypoglycemia.
Asymptomatic hypoglycaemia can be diagnosed by routine
blood glucose monitoring and should alert the patient and
clinician to the possibility of developing impaired awareness
of hypoglycaemia. Enormous advances have been made in
our knowledge of the physiology and patho-physiology of
impaired awareness of hypoglycemia and these have to be
put with practice. This review has tried to show, that much
can be done to reduce the frequency and severity of
hypoglycemia unawareness without compromising glycaemic
control. Though the debate on the risk of a single severe
episode of hypoglycaemia compared to the risk of recurrent
minor episodes of hypoglycaemia continues, both should
ideally be avoided, especially in children. The good news is
that prevention of hypoglycemia largely, if not fully, reverses
unawareness and improves counter-regulation to
hypoglycemia.
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